Neurodevelopment in Children Born to HIV-Infected Mothers by Infection and Treatment Status

  title={Neurodevelopment in Children Born to HIV-Infected Mothers by Infection and Treatment Status},
  author={Kirsty Le Doare and Ruth M Bland and Marie-Louise Newell},
  pages={e1326 - e1344}
BACKGROUND: We reviewed the impact of HIV, HIV exposure, and antiretroviral therapy/prophylaxis on neurodevelopmental outcomes of HIV-infected and HIV-exposed-uninfected infants and children. METHODS: A literature search of Medline, Embase, PsychINFO, Web of Science, PubMed, and conference Web sites (1990–March 2011) using the search terms, infant, child, HIV, neurodevelopment, cognition, language, and antiretroviral therapy, identified 31 studies of HIV/antiretroviral exposure using… 

Figures from this paper

Neurodevelopmental outcomes in HIV-exposed-uninfected children versus those not exposed to HIV

It is concluded that HEU children evidence reductions in some neurodevelopmental outcomes compared to HUU; however, these differences are small and it remains unclear to what extent they have immediate and long-term clinical significance.

Neurodevelopment of HIV-Exposed and HIV-Unexposed Uninfected Children at 24 Months

HEU children performed equally well on neurodevelopmental assessments at 24 months of age compared with HUU children, and results suggesting no adverse impact of in-utero HIV and antiretroviral exposure on early neurodevelopment are reassuring.

Brain Imaging and Neurodevelopment in HIV-uninfected Thai Children Born to HIV-infected Mothers

No differences in neuroanatomical or brain integrity measures were detectable in HEU children compared with age-matched and sex-matched controls (HUU children), suggesting sufficient power to detect subtle associations that were present.

Neurological development of children who are HIV‐exposed and uninfected

This work reviews seminal and recent evidence on the neurological development of CHEU and associations with early life HIV/antiretroviral exposure, and highlights the numerous exposures and universal risk factors for CHEU developmental disorders.

Neurodevelopmental and behavioural outcome of the HIV-exposed uninfected infant and child

There were mixed findings on neurodevelopmental outcome in children under three years of age from LMIC, with limited research on behaviour, while heterogeneity of CDAT use complicated study comparisons.

In-utero exposure to antiretrovirals and neurodevelopment among HIV-exposed-uninfected children in Botswana

Maternal ART with breastfeeding does not appear to have an adverse effect on neurodevelopment in HIV-exposed-uninfected children exposed in utero to three-drug combination antiretroviral therapy vs. zidovudine monotherapy.

Maternal Factors Associated With Infant Neurodevelopment in HIV-Exposed Uninfected Infants

Risks for delayed infant cognitive development to be associated with the use of ARV during pregnancy and intimate partner violence, although findings merit replication due to the low sample size.

Neruodevelopmental Outcomes in Preschool Children Living With HIV-1 Subtypes A and D in Uganda

ND scores among preschool children were similar for subtypes A and D, with few potential differences on language production and memory outcomes that favored subtype A, compared to previously reported differences in ND outcomes of school-age children by HIV-1 subtype.



Neurodevelopment and In Utero Antiretroviral Exposure of HIV-Exposed Uninfected Infants

Mental and motor functioning scores were not lower for infants with in utero ARV exposure compared with no exposure, and continued evaluation of uninfected children with in Utero ARVs exposure for long-term adverse outcomes is important.

Effect of perinatally acquired human immunodeficiency virus infection on neurodevelopment in children during the first two years of life.

Children with serious HIV symptomatology appear to be at very high risk for serious developmental impairments, HIV-infected children not highly symptomatic have relatively normal neurodevelopment, and uninfected children of HIV- Infected mothers do not seem to be adversely affected by the mother's HIV infection.

Neurodevelopmental Functioning in HIV-Infected Infants and Young Children Before and After the Introduction of Protease Inhibitor–Based Highly Active Antiretroviral Therapy

There was evidence of limited improvement in the HIV+ infants relative to their uninfected peers and among infants who had Bayley II evaluations before and after starting a protease inhibitors, there was a trend to improved mental and motor scores after initiation of protease inhibitor therapy.

A Prospective Controlled Study of Neurodevelopment in HIV-Uninfected Children Exposed to Combination Antiretroviral Drugs in Pregnancy

It is suggested that perinatal highly active antiretroviral therapy exposure is not associated with altered development and behavior at 18 to 36 months of age.

Neurodevelopment, Growth, and Viral Load in HIV-Infected Infants

In INF infants, decreased linear growth was positively correlated with developmental delay and growth and development were both correlated with HIV viral load, and infants with high plasma HIV RNA copies at 6 months of life were more likely to exhibit severe growth and developmental delay than infants with a lower viral burden.

Early neurodevelopmental growth in children with vertically transmitted human immunodeficiency virus infection.

Early and persistent delay in motor development and deceleration in mental development in late infancy distinguishes many children who are HIV infected from exposed but uninfected children, but there is significant variability in early neurodevelopmental outcome among children with HIV infection.

The effects of HIV on cognitive and motor development in children born to HIV-seropositive women with no reported drug use: birth to 24 months.

Over the first 24 months of life, the mean rate of development of HIV-infected infants is significantly slower than that of non Infected infants born to seropositive mothers, even when the effects are not confounded with those of prenatal drug exposure.

Timing of perinatal human immunodeficiency virus type 1 infection and rate of neurodevelopment. The Women and Infant Transmission Study Group.

Early HIV-1 infection increases a child's risk for poor neurodevelopmental functioning within the first 30 months of life.

Neurodevelopmental testing of children born to human immunodeficiency virus type 1 seropositive and seronegative mothers: a prospective cohort study in Kigali, Rwanda.

HIV-1-infected children are more frequently developmentally delayed than uninfected children during the first 2 years of life in this African population and this developmental delay is related to the AIDS stage of pediatric HIV infection.

Effects of Perinatal HIV Infection and Associated Risk Factors on Cognitive Development Among Young Children

An early AIDS-defining illness increased the risk of chronic static encephalopathy during the preschool and early school age years and a number of factors were found to have significant effects on the mean scores of children in all 3 groups; however, they were not related to the rate at which learning occurred.